Azelaic acid
ALSO — NONANEDIOIC ACID
An ingredient used in distinct acne, rosacea and pigment-treatment contexts. A percentage without the vehicle, indication and proposed combination cannot identify the relevant evidence.
The marker is a representative concentration from the cited records. The bar includes approved and compounded preparations recorded here. It is not a recommended dose, a minimum effective strength or a claim that other concentrations are untested. Evidence depends on the vehicle, indication and trial population.
The shaded band is the depth this molecule is understood to reach. Anything below it is out of scope, whatever the label says.
Normalises keratinisation, reduces reactive oxygen species and interferes with cathelicidin processing — the pathway now understood to be central to rosacea. Also a competitive tyrosinase inhibitor, which is why it turns up in pigment formulas.
Multicentre randomised, vehicle-controlled; mean subject age 50.6, range 19–92
N=961 · 12 WK · DOUBLE-BLIND
Multicentre randomised, vehicle-controlled; mean subject age 50.6, range 19–92
N=401 · 12 WK · DOUBLE-BLIND
The Custom Formula acne review, Agency Dark Spot review and Skin Medicinals rosacea review discuss different treatment targets. The presence of azelaic acid across their candidate menus does not make the prescriptions or expected outcomes equivalent. Check which ingredients were actually selected.
A register can identify concentrations attached to particular trials without surveying every concentration ever studied. Below the marker does not mean no evidence exists anywhere; above it does not mean more effective. Match the finished preparation and endpoint where evidence is available, and describe the remaining uncertainty.
Ask why azelaic acid is included, whether another active addresses a separate concern, and how the regimen will be reviewed. For rosacea, persistent redness and inflammatory bumps are distinct targets. For pigment concerns, ask about the diagnosis and overall plan rather than selecting a formula by its ingredient count.
One-time and subscription prices, possible ingredient combinations and consultation requirements. Marketing outcomes are not used as controlled-trial evidence. Checked 13 September 2026.
Current $110 price, 18 g / 60-day supply, possible hydroquinone and non-hydroquinone formulas, and clinician-directed transitions. Checked 13 September 2026.
Three named ingredients and the distinction between platform, independent prescriber and dispensing pharmacy. The displayed retail comparisons are not patient-specific savings or a quote for the compound. Checked 13 September 2026.
Different treatment targets for persistent redness, inflammatory bumps and eye involvement. Evidence for individual treatments does not establish a compounded combination's performance. Checked 13 September 2026.
One reader gets a 12 months CoreAge Rx derm plan — the compounded, physician-reviewed subscription we take apart in the register. Worth $780. Leave an address and you are entered.
VALUE IS THE PUBLISHED $64.99/MONTH SUBSCRIPTION PRICE OVER TWELVE MONTHS, AS RECORDED IN R-10. NO PURCHASE NECESSARY. WE REVIEW COREAGE RX — WE DO NOT SELL IT.